ORTIN GLOBAL cash flow

·Pharma & HealthChart ›
Latest FY26
Cash from operations
−₹0.6cr−₹0.4 cr in FY25
Capital spending
₹0.0cr−100.0% on FY25
Free cash flow
−₹0.6cr−₹0.4 cr in FY25
Cash from financing
₹0.8cr+129.3% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—0.00.00.20.3
—0.00.00.50.4
Changes in working capital
—0.00.02.5−0.9
—0.11.51.7−0.2
—−0.40.00.00.0
—−0.0−0.10.00.0
—−0.3−0.5−1.9−0.1
—−0.0−0.0−1.50.8
—0.9−0.4−0.1−0.5
—0.0−0.0−0.20.0
Cash from operating activities
−0.9−0.7−0.8−7.1−0.1
—0.20.41.3−0.1
—−0.6−0.4−5.8−0.2
—0.00.02.10.0
—−0.6−0.4−3.7−0.2
Cash from investing activities
—0.00.00.00.0
—0.00.011.50.0
—−0.00.00.00.0
—0.0−0.011.5−0.0
Cash from financing activities
—0.0−1.60.01.2
—−0.80.01.20.0
—0.00.00.50.4
—−0.01.9−1.80.1
—0.80.3−3.50.9
—0.2−0.14.30.7
—0.2−0.14.30.7
———0.5−3.2
Reference items
−1.2−1.0−0.9−6.50.5
−1,618.7%−1,030.1%−258.2%−309.6%8.7%
−0.6−0.6−0.4−3.7−0.2
——−2.0−8.8—
−₹0.69−₹0.69−₹0.51−₹4.51−₹0.27
—0.76×0.48×0.46×3.26×
——0.00.50.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ORTINGLOBE₹12.41

ORTIN GLOBAL LIMITED

· Pharma & Health
₹ CrorePeersLASAMANGALAMBIOFILCHEMVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹10.1 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation0.30.20.00.0—
+ Finance Costs0.40.50.00.0—
Changes in Working Capital
+ Inventories-0.92.50.00.0—
+ Trade Receivables — Current-0.21.71.50.1—
+ Other Financial Assets — Current0.00.00.0-0.4—
+ Other Financial Assets — Non-current0.00.0-0.1-0.0—
+ Other Current Assets-0.1-1.9-0.5-0.3—
+ Trade Payables — Current0.8-1.5-0.0-0.0—
+ Other Current Liabilities-0.5-0.1-0.40.9—
+ Provisions — Current0.0-0.2-0.00.0—
Cash from Operating Activities
Profit Before Tax (per I/S)-0.1-7.1-0.8-0.7-0.9
+ Total Adjustments (incl. Working Capital)-0.11.30.40.2—
Cash from Operations (pre-tax)-0.2-5.8-0.4-0.6—
+ Other Inflows / (Outflows) — Operating0.02.10.00.0—
Cash from Operating Activities-0.2-3.7-0.4-0.6—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)0.00.00.00.0—
+ Disp of Fixed Assets0.011.50.00.0—
+ Acq of Other Long-term Assets0.00.00.0-0.0—
Cash from Investing Activities-0.011.5-0.00.0—
Cash from Financing Activities
+ Proceeds from Borrowings1.20.0-1.60.0—
+ Repayment of Borrowings0.01.20.0-0.8—
+ Interest Paid0.40.50.00.0—
+ Other Inflows / (Outflows) — Financing0.1-1.81.9-0.0—
Cash from Financing Activities0.9-3.50.30.8—
Net Changes in Cash (pre-FX)0.74.3-0.10.2—
Net Changes in Cash0.74.3-0.10.2—
Closing Cash-3.20.5———
Reference Items
EBITDA0.5-6.5-0.9-1.0-1.2
EBITDA Margin %8.65-309.60-258.21-1,030.05-1,618.67
Free Cash Flow (CFO − Capex)-0.2-3.7-0.4-0.6-0.6
Free Cash Flow to Equity—-8.8-2.0——
Free Cash Flow per Basic Share-0.27-4.51-0.51-0.69-0.69
Cash Flow to Net Income3.260.460.480.76—
Cash Paid for Interest0.40.50.0——
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.